M. A. Altinoz Et Al. , "Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale," Medical Hypotheses , vol.68, no.6, pp.1342-1347, 2007
Altinoz, M. A. Et Al. 2007. Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale. Medical Hypotheses , vol.68, no.6 , 1342-1347.
Altinoz, M. A., ÖZDİLLİ, K., Carin, M. N., & Gedikoglu, G., (2007). Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale. Medical Hypotheses , vol.68, no.6, 1342-1347.
Altinoz, Meric Et Al. "Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale," Medical Hypotheses , vol.68, no.6, 1342-1347, 2007
Altinoz, Meric A. Et Al. "Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale." Medical Hypotheses , vol.68, no.6, pp.1342-1347, 2007
Altinoz, M. A. Et Al. (2007) . "Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale." Medical Hypotheses , vol.68, no.6, pp.1342-1347.
@article{article, author={Meric A. Altinoz Et Al. }, title={Medroxyprogesterone - valproic acid - aspirin. MVA regime to reduce transfusion associated mortality in late-term hemoglobinopathies. Hypothesis and rationale}, journal={Medical Hypotheses}, year=2007, pages={1342-1347} }